- Pfizer Inc. (NYSE: PFE) today held its Annual Meeting of Shareholders. Preliminary results from the Annual Meeting indicate that the company's 12 director nominees were re-elected to one-year terms and that shareholders ratified the selection of KPMG LLP as Pfizer's independent registered public accounting firm for the 2024 fiscal year. In addition, shareholders supported the board-sponsored proposals to approve the amended and restated 2019 stock plan and, separately, the compensation of the company's named executive officers, on an advisory basis.
In other voting, shareholders did not support the three shareholder-sponsored proposals.
"We thank all shareholders for their engagement and participation today and for their ongoing support. 2023 was a year of challenges and accomplishments and one that provided an opportunity to position Pfizer for the next wave of progress and growth. We believe we have the right products, the right people and the right plan for great success in 2024 and beyond," stated Albert Bourla, Pfizer Chairman and Chief Executive Officer.
The final results are subject to verification by the independent inspectors of election. The final results will be reported on a Current Report on Form 8-K to be filed by Pfizer with the U.S. Securities and Exchange Commission in the next few days.
